HIBUX Fees and Costs — Hancock Horizon Burkenroad Small Cap Fund, Institutional Class

Data updated: 2021-08-26

The net expense ratio is 1.00%: a 0.80% management fee plus 0.41% other expenses, less a 0.21% fee waiver. There are no sales loads or redemption fees. In fiscal 2020 the fund paid $476K in broker commissions, 0.3606% of average net assets, and portfolio turnover was 31%.

HIBUX Fees and Expenses

Annual operating expenses and sales charges of HIBUX. Prospectus, as of April 30, 2021.

Annual operating expenses
Management fee0.80%
12b-1 fee0.00%
Other expenses0.41%
Gross expense ratio1.21%
Fee waiver−0.21%
Net expense ratio1.00%
Sales charges
Max front load—
Max deferred load—
Redemption fee—
Expense limitation in place (N-CEN)Yes
Fees waived or reduced during the yearYes
Waived fees subject to recoupmentYes

HIBUX Costs Over Time

On $10,000 invested in HIBUX, assuming 5% a year before costs, total costs come to $845 over 5 years, cutting the return by 1.43% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).

$10,000 investedSell after 1 yearSell after 3 yearsSell after 5 years
Value before costs$10,500$11,576$12,763
Fund expenses (net expense ratio 1.00%)$105$326$564
Trading costs (broker commissions)$38$118$203
Lost growth on money paid in costs$0$22$78
Total costs$143$466$845
Value after costs$10,357$11,110$11,918
Impact on return, per year1.43%1.43%1.43%

HIBUX Trading Costs

Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2020.

  • Explicit cost rate (commissions ÷ average net assets): 0.3606%
  • Total broker commissions: $476K
  • Bought from dealers (principal trades, not a cost): —
  • Portfolio turnover (prospectus): 31%
  • Securities lending: none during the year

HIBUX Agency Brokers

Commissions paid.

BrokerAmountShare
ITGI$476K100.00%

For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.